- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
CIBC Bancorp USA Inc. Invests $24.42 Million in Gilead Sciences
The investment firm bought a new position in the biopharmaceutical company's stock in the third quarter.
Mar. 19, 2026 at 8:24am
Got story updates? Submit your updates here. ›
CIBC Bancorp USA Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 219,986 shares of the biopharmaceutical company's stock, valued at approximately $24,418,000.
Why it matters
Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. CIBC Bancorp USA Inc.'s significant investment in the company suggests confidence in Gilead's future prospects and potential for growth.
The details
The 219,986 shares purchased by CIBC Bancorp USA Inc. represent a new position for the investment firm in Gilead Sciences. The shares were valued at approximately $24.42 million, indicating a substantial investment in the biopharmaceutical company.
- CIBC Bancorp USA Inc. bought the Gilead Sciences shares in the 3rd quarter of 2026.
The players
CIBC Bancorp USA Inc.
An investment firm that manages assets and provides financial services.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.
The takeaway
CIBC Bancorp USA Inc.'s substantial investment in Gilead Sciences suggests confidence in the biopharmaceutical company's future growth and potential, as Gilead continues to be a leader in the development of innovative antiviral therapies.
